SABCS 2024 详细日程公布！你对哪些研究最感兴趣？

标题：Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial

Imlunestrant（口服 SERD）单药或联合阿贝西利治疗 ET 经治的 ER+/HER2- 晚期乳腺癌：III 期 EMBER-3 研究结果

讲者：Komal Jhaveri，Memorial Sloan Kettering Cancer Center

标题：Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗初治 HER2+ mBC：III 期 PHILA 试验的预先指定 PFS 最终分析

讲者：徐兵河，中国医学科学院肿瘤医院

标题：HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial

HER2-ADC SHR-A1811 在 HER2+ 早期乳腺癌新辅助治疗中的研究：一项前瞻性、随机、开放标签、Ⅱ 期试验

讲者：李俊杰，复旦大学附属肿瘤医院

标题： PRO B – a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients

PRO B：一项优效性随机对照试验，评估 mBC 患者症状监测的有效性

讲者：Maria Margarete Karsten，Charité-Universitätsmedizin

标题：Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study

降低风险手术与携带 BRCA 突变的年轻乳腺癌患者生存情况的关系：一项国际队列研究的结果

讲者：Matteo Lambertini，University of Genova

标题：OlympiA-Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow

OlympiA：一项多中心、随机、安慰剂对照、III 期研究，评估（新）辅助化疗后奥拉帕利用于 BRCA1/2 突变的高危 HER2- 原发乳腺癌患者；长期随访结果

讲者：Judy Garber，Dana-Farber Cancer Institute

标题：Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial

单纯内分泌治疗或放疗治疗 70 岁以上 Luminal 型早期乳腺癌女性患者（EUROPA）：一项 III 期研究的预设期中分析

讲者：Icro Meattini，University of Florence

标题：Impact of Tamoxifen Only after Breast Conservation Surgery for 'Good Risk' Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial

NRG Oncology/RTOG 9804 和 ECOG-ACRIN E5194 试验结果：保乳手术后仅使用他莫昔芬对「Good Risk」导管原位癌的影响

讲者：Jean Wright，University of North Carolina School of Medicine

标题：Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators

「中危」乳腺癌切除术后放疗是否影响总生存率？BIG 2-04 MRC SUPREMO 随机试验的 10 年结果：代表 SUPREMO 试验研究者

讲者：Ian Kunkler，Edinburgh Cancer Centre，University of Edinburgh

标题：Early Oncologic Outcomes Following Active Monitoring or Surgery (+/-Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)

低风险 DCIS 主动监测或手术（+/-放疗）后的早期肿瘤预后：手术 vs 监测，伴或不伴内分泌治疗（COMET）研究（AFT-25）

讲者：Eun-Sil Hwang，Duke University School of Medicine

标题：Patient Reported Outcomes Following Active Monitoring or Surgery (+/-Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)

主动监测或手术（+/-放疗）治疗低风险 DCIS 的患者报告结果：手术 vs 监测，伴或不伴内分泌治疗（COMET）研究（AFT-25）

讲者：Ann Partridge，Dana-Farber Cancer Institute

标题：No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial

豁免腋窝手术 vs 腋窝前哨淋巴结活检治疗行保乳手术的早期侵袭性乳腺癌患者：INSEMA 研究最终主要结果

讲者：Toralf Reimer，Universitätsmedizin Rostock

标题：Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists』 Collaborative Group (EBCTCG) database

EBCTCG 数据库中 206904 名妇女的超重、肥胖以及预后情况

讲者：Hongchao Pan，University of Oxford

标题：A long-term image-derived AI risk model for primary prevention of breast cancer

用于乳腺癌一级预防的长期图像衍生 AI 风险模型

讲者：Mikael Eriksson，Karolinska Institutet

标题：APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer

APOBEC3 突变诱导乳腺癌中促进耐药基因组变化

讲者：Avantika Gupta，Memorial Sloan Kettering Cancer Center

标题：Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy

评估尼拉帕利或安慰剂用于经最终治疗后伴有分子残留的 TNBC 或 HER2+ BRCA 突变乳腺癌患者的随机、III 期、双盲 ZEST 研究的 ctDNA 监测结果

讲者：Nicholas Turner，Ralph Lauren Centre for Breast Cancer Research

标题：Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer

蒽环类药物对高基因组风险淋巴结阴性 HR+/HER2- 乳腺癌的影响

讲者：Nan Chen，University of Chicago Medicine

标题：(Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ETresponse: final survival results from the WSG ADAPT-HR+/HER2- chemotherapytrial

基于 ET 治疗反应，在基因或临床高危 HR+/HER2- 早期乳腺癌患者中使用新辅助白蛋白紫杉醇周疗 vs 溶剂型紫杉醇 q2w，序贯 EC q2w 治疗：WSG ADAPT-HR+/HER2- 化疗研究的最终生存分析结果

讲者：Sherko Kuemmel，German Medical Institute

标题：NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triplenegative breast cancer

NSABP B-59/GBG-96-GeparDouze：一项探索新辅助化疗联合阿替利珠单抗或安慰剂后辅助阿替利珠单抗或安慰剂治疗 II-III 期 TNBC 的随机、双盲、III 期临床研究

讲者：Charles Geyer，University of Pittsburgh

标题：Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, doubleblind, phase 3 trial

新辅助卡瑞利珠单抗联合化疗治疗早期或局部晚期 TNBC：一项随机、双盲、Ⅲ 期试验

讲者：邵志敏，复旦大学附属肿瘤医院

标题：In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss

原位检测乳腺癌中单个经典 MHC-I 基因产物可识别基因特异性和亚型特异性偏置抗原呈递缺失

讲者：Paula Gonzalez-Ericsson，Vanderbilt-Ingram Cancer Center

标题：Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer

真实世界临床和基因组数据的多模式整合，用于预测 CDK4/6 抑制剂在 HR+/HER2- 转移性乳腺癌患者中的预后

讲者：Enrico Moiso，Memorial Sloan Kettering Cancer Center

标题：Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer

CALGB 40603（Alliance）的配对 DNA 和 RNA 分析揭示了 II-III 期 TNBC 的分子和预后

讲者：Brooke Felsheim，UNC School of Medicine

标题：Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women

可手术乳腺癌不立即手术或减少手术范围的长期影响：对 2514 名妇女进行的四项随机试验的患者水平荟萃分析

讲者：Robert Hills，University of Oxford

标题：MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer

MARGOT/TBCRC052：一项对比新辅助紫杉醇/pertuzumab（马吉妥昔单抗）/帕妥珠单抗（TMP）vs 紫杉醇/曲妥珠单抗/帕妥珠单抗（THP）治疗 II-III 期 HER2+ 乳腺癌患者的 II 期研究

讲者：Adrienne Waks，Dana-Farber Cancer Institute

标题：Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy-PADMA study

比较 ET 联合哌柏西利和标准单药化疗治疗高危 HR+/HER2- 转移性乳腺癌患者疗效和化疗适应症的 III 期随机 PADMA 研究初步结果

讲者：Sibylle Loibl，German Cooperative Group

标题：Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrinebased therapy: additional analysis from DESTINY-Breast06

T-DXd vs 医师选择化疗方案（TPC）基于既往内分泌治疗的疾病进展速度的疗效和安全性：DB06 研究的额外分析

讲者：Aditya Bardia，UCLA David Geffen School of Medicine

标题：ROSC (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2-chemotherapy-trial

根据 ET 反应，在基因组或临床高风险的 HR+/HER-早期乳腺癌中，新辅助 nab-PAC q2w vs sb-PAC q2w 序贯 EC q2w：来自 WSG ADAPT-HR+/HER2- 化疗试验的最终生存结果

讲者：Sherko Kuemmel，German Medical Institute

标题：Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)

SOLTI VALENTINE 研究主要结果：HER3-DXd 单药或联合来曲唑治疗高危 HR+/HER2- EBC 的 II 期新辅助随机试验

讲者：Mafalda Oliveira，Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)

标题：Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC

III 期 KN522 研究的探索性生物标志物分析结果：新辅助帕博利珠单抗/安慰剂联合化疗后辅助帕博利珠单抗/安慰剂治疗早期 TNBC

讲者：Joyce O’shaughnessy，Baylor-Sammons Cancer Center

标题： Prediction of Prognosis and Efficacy of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients Based on Tertiary Lymphoid Structures

基于三级淋巴结构预测 HER2 阳性乳腺癌患者新辅助治疗的疗效和预后

讲者：张克兢，中南大学湘雅医院

标题：Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial

达尔西利或安慰剂联合来曲唑或阿那曲唑作为 HR+/HER2- 晚期乳腺癌女性患者的一线治疗：Ⅲ 期 DAWNA-2 试验中预设的 PFS 最终分析

讲者：徐兵河，中国医学科学院肿瘤医院

标题：Tibremciclib (BPI-16350) plus fulvestrant versus placebo plus fulvestrant for patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: Updated analysis of the phase III study

Tibremciclib（BPI-16350）或安慰剂联合氟维司群治疗内分泌治疗后进展的 HR+/HER2- 晚期乳腺癌患者：Ⅲ 期研究的更新分析

讲者：胡夕春，复旦大学附属肿瘤医院

标题：First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression

一线瑞波西利联合内分泌治疗（ET）与联合化疗在临床浸润性 HR+/HER2- 晚期乳腺癌患者中的比较：基于内在亚型、基因和标志物表达的 RIGHT Choice 研究亚组分析

讲者：卢彦伸，中国台湾大学医学院附属医院

标题：Integrating ctDNA and Tumor Fraction Features for Deciphering Molecular Response and Resistance Mechanism to Endocrine Therapy and CDK4/6 Inhibition in Advanced HR-positive Metastatic Breast Cancer

整合 ctDNA 和肿瘤分数特征在解读晚期 HR+ 转移性乳腺癌患者对内分泌治疗和 CDK4/6 抑制剂的分子反应和耐药机制中的应用

讲者：Hao Liao 北京大学肿瘤医院

标题：Tislelizumab plus sitravatinib and nab-paclitaxel in patients with untreated locally recurrent or metastatic triple negative breast cancer (TNBC): updated efficacy and safety results

替雷利珠单抗联合 sitravatinib 和白蛋白结合型紫杉醇治疗未经治的局部复发或转移性 TNBC 患者：疗效和安全性结果更新

讲者：刘西禹，复旦大学附属肿瘤医院

标题：Induction of Cisplatin/abraxane/pembrolizumab followed by pembrolizumab ± Olaparib Maintenance in triple-negative Metastatic breast cancer patients (COMPLEMENT) – A Randomized, Open-label, Phase II Study

顺铂/白蛋白结合型紫杉醇/帕博利珠单抗诱导治疗后，帕博利珠单抗 ± 奥拉帕利维持治疗在转移性 TNBC 患者中的疗效（COMPLEMENT）：一项随机、开放标签、Ⅱ 期研究

讲者：胡夕春，复旦大学附属肿瘤医院

标题：Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)

依沃西单抗联合化疗作为 TNBC 患者一线治疗的安全性和疗效评估：一项随机、开放标签、Ⅱ 期研究

讲者：欧阳取长，湖南省肿瘤医院

标题：Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated wtih First Line PM8002/BNT327 in Combination with Nab-Paclitaxel in Phase Ib/II Study

接受一线 PM8002/BNT327 联合白蛋白结合型紫杉醇治疗的局部晚期或转移性 TNBC 患者的中位总生存期（OS）：一项随机、开放标签、Ⅱ 期研究

讲者：吴炅，复旦大学附属肿瘤医院

标题：The tumor heterogeneous overexpressed CD155 promotes treatment resistance in HER2-positive breast cancer through immune microenvironment modulation

肿瘤异质性过表达 CD155 通过免疫微环境调节促进 HER2+ 乳腺癌治疗耐药性

讲者：张怡，复旦大学附属肿瘤医院

标题：ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases

ZN-1041，一种潜在的同类最佳 BBB 穿透性 HER2 抑制剂，在乳腺癌脑转移患者中具有很高的抗肿瘤活性

讲者：马飞，中国医学科学院肿瘤医院

标题：A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors

评估 TL938 在 HER2+ 晚期实体瘤患者中的安全性、有效性和药代动力学的一项 Ⅰ 期研究

讲者：石远凯，中国医学科学院肿瘤医院

标题：ACE-Breast-08: a phase I study of ARX788, a novel anti-HER2 antibody-drug conjugate, in patients with TKI pretreated HER2 positive advanced breast cancer

ACE-Breast-08：一种新型抗 HER2-ADC ARX788，在 TKI 经治的 HER2+ 期乳腺癌患者中的 Ⅰ 期研究

讲者：王晓稼，浙江省肿瘤医院

标题：A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis

维迪西妥单抗（一种抗 HER2 单克隆抗体-MMAE 偶联物）与拉帕替尼联合卡培他滨在 HER2+ 晚期乳腺癌伴肝转移患者中的疗效：一项随机、开放标签的 Ⅲ 期研究

讲者：王佳玉，中国医学科学院肿瘤医院

标题：Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer

GQ1005，一种有潜力的 HER2-ADC，在转移性 HER2+ 乳腺癌患者中的疗效和安全性研究

讲者：王碧芸，复旦大学附属肿瘤医院

标题：Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study

SHR-A1811，一种抗 HER2-ADC，在 391 例经过大量预处理的 HER2 表达或突变的多发性实体瘤患者中的疗效和安全性：一项全球性、多中心、首例人体、Ⅰ 期研究

讲者：姚和瑞，中山大学孙逸仙纪念医院

标题：MRI improves multi-modal AI system for breast cancer diagnosis and prognosis

磁共振成像（MRI）提高了用于乳腺癌诊断和预后的多模态人工智能系统的效能

讲者：Yanqi Xu，中国药科大学

标题：HDACi combined with anthracycline elicits interactions between MHC-II+ triple-negative breast cancer and CD69+CD4+Trm orchestrating synergistic immunotherapy

HDAC 抑制剂联合蒽环类药物引发 MHC-II+ TNBC 与 CD69+CD4+Trm 协同促进免疫治疗之间的相互作用

讲者：王泽浩，复旦大学附属肿瘤医院

PS14-02：

PS14-03：

PS14-04：